Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02139111 · ClinicalTrials.gov registry record · Phase 3

PRC-063 in Adolescent ADHD

A Phase 3 study of ADHD, sponsored by Rhodes Pharmaceuticals, L.P..

Completed
Registry status
Phase 3
Development phase
360
Enrollment target
20
Study locations

NCT02139111: Completed Phase 3 study of ADHD, sponsored by Rhodes Pharmaceuticals, L.P..

NCT02139111 is a Phase 3 study of ADHD that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 360 participants, above the 185-participant average among 75 other ADHD trials with a reported enrollment target (95% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02139111, a Phase 3 study of ADHD, has completed, sponsored by Rhodes Pharmaceuticals, L.P..

COMPLETED
Registry status
Phase 3
Development phase
360 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG PRC-063 25 mg
  • DRUG PRC-063 45 mg
  • DRUG PRC-063 70 mg
  • DRUG PRC-063 85 mg

Study Locations (20)

Florida

  • Florida Clinical Research Center - Bradenton
  • Sarkis Clinical Research - Gainesville
  • Sarkis Clinical Trials - Gainesville
  • CNS Healthcare Jacksonville - Jacksonville
  • Florida Clinical Research Center - Maitlin
  • Clinical Neuroscience Solutions - Orlando
  • Miami Research Associates - South Miami
  • Stedman Clinical Trials - Tampa

California

  • UCLA - Los Angeles
  • Synergy Clinical Research - National City
  • Newport Beach Clinical Research Associates, Inc. - Newport Beach
  • Orange County Neuro Phychiatry Research Centre - Orange

North Carolina

  • Duke University Medical Center - Durham
  • Wake Research Associates - Raleigh

Idaho

  • Advanced Clinical Research - Boise

Maryland

  • Kennedy Krieger Institute - Baltimore

Nevada

  • Center for Psychiatry and Behavioral Medicine Inc. - Las Vegas

Ohio

  • University of Cincinnati - Cincinnati

Oklahoma

  • IPS Research Company - Oklahoma City

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2014-04
Est. Completion 2015-05
Phase Phase 3
Rhodes Pharmaceuticals, L.P.

10 total trials

What the finished NCT02139111 record still lists

NCT02139111 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 185-participant average among 75 other ADHD trials with a reported enrollment target (95% higher).

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02139111 names 20 study sites across 9 states, led by Florida, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02139111 about?

NCT02139111 is a clinical study titled "PRC-063 in Adolescent ADHD". The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.

What is the current status of trial NCT02139111?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2014-04. Estimated completion is 2015-05.

What conditions does trial NCT02139111 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT02139111?

The interventions under investigation include: Placebo (DRUG), PRC-063 25 mg (DRUG), PRC-063 45 mg (DRUG), PRC-063 70 mg (DRUG), PRC-063 85 mg (DRUG).

Who is sponsoring clinical trial NCT02139111?

This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02139111 being conducted?

This trial has 20 study locations across California, Florida, Idaho, Maryland, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02139111's enrollment target sits among peer trials

360 7th of 75 higher than 69 of 75 other ADHD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04160000 · 360 participants · Phase 4

    Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02139111, the US trial registry maintained by the National Library of Medicine. NCT02139111 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.